Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer

Christi M. J. Steendam, G. D. Marijn Veerman, Melinda A. Pruis, Peggy Atmodimedjo, Marthe S. Paats, Cor van der Leest, Jan H. von der Thusen, David C. Y. Yick, Esther Oomen-de Hoop, Stijn L. W. Koolen, Winand N. M. Dinjens, Ron H. N. van Schaik, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Hendrikus Jan Dubbink, Anne-Marie C. Dingemans

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Article number3179
Number of pages17
JournalCancers
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 2020

Keywords

  • NSCLC
  • EGFR
  • TKI
  • cfDNA
  • plasma conversion
  • TP53 mutation
  • T790M mutation
  • pharmacokinetics
  • TYROSINE KINASE INHIBITOR
  • MASS-SPECTROMETRY
  • CHINESE PATIENTS
  • OSIMERTINIB
  • MUTATIONS
  • ERLOTINIB
  • TP53
  • PHARMACOKINETICS
  • QUANTIFICATION
  • PROGRESSION

Cite this